Spark Therapeutics Company Profile (NASDAQ:ONCE)

Analyst Ratings

Consensus Ratings for Spark Therapeutics (NASDAQ:ONCE) (?)
Ratings Breakdown: 1 Sell Rating(s), 4 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $60.67 (10.95% upside)

Analysts' Ratings History for Spark Therapeutics (NASDAQ:ONCE)
Show:
DateFirmActionRatingPrice TargetActions
7/21/2016Chardan CapitalSet Price TargetHold$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/14/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Royal Bank Of CanadaInitiated CoverageOutperform$70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016SunTrust Banks Inc.Boost Price TargetBuy$64.00 -> $72.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2016Jefferies GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016WedbushReiterated RatingUnderperform$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Cowen and CompanyReiterated RatingBuy$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Evercore ISIInitiated CoverageBuy$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Goldman Sachs Group Inc.Initiated CoverageBuy -> Neutral$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/24/2015WunderlichDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/11/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Credit Suisse Group AGInitiated CoverageOutperform$76.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015Sanford C. BernsteinInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2015Rodman & RenshawInitiated CoverageBuy$71.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Spark Therapeutics (NASDAQ:ONCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/4/2016Q116($0.84)($0.95)$1.48 million$1.29 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($0.73)($0.24)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.48)($0.70)$4.43 million$1.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.13)($0.60)$4.50 million$1.29 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.61)($0.58)$1.20 million$1.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Spark Therapeutics (NASDAQ:ONCE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($1.04)($0.80)($0.88)
Q2 20164($1.00)($0.83)($0.89)
Q3 20164($1.05)($0.88)($0.95)
Q4 20164($1.09)($0.90)($0.99)
Q1 20171($1.08)($1.08)($1.08)
Q2 20171($1.08)($1.08)($1.08)
Q3 20171($1.06)($1.06)($1.06)
Q4 20171($1.01)($1.01)($1.01)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Spark Therapeutics (NASDAQ:ONCE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Spark Therapeutics (NASDAQ:ONCE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/18/2016Jeffrey D MarrazzoCEOSell5,000$52.53$262,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2016Coelho Rogerio VivaldiInsiderSell7,000$53.03$371,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2016Barge Joseph LaInsiderSell3,000$52.24$156,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2016Hospital Of Philade Children'sMajor ShareholderSell1,000,000$42.30$42,300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016Jeffrey D MarrazzoCEOSell5,000$46.49$232,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2016Anand MehraDirectorSell500$60.00$30,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Katherine A HighInsiderSell10,000$54.42$544,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Barge Joseph LaInsiderSell10,000$47.65$476,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Stephen W WebsterCFOSell20,000$50.39$1,007,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Jeffrey D MarrazzoCEOSell25,000$46.01$1,150,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2016Coelho Rogerio VivaldiInsiderSell7,000$40.02$280,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Hospital Of Philade Children'sMajor ShareholderSell131,505$44.18$5,809,890.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015Hospital Of Philade Children'sMajor ShareholderSell1,000,000$44.18$44,180,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Katherine A HighInsiderSell10,000$55.31$553,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Anand MehraDirectorSell22,961$60.01$1,377,889.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Katherine A HighInsiderSell10,000$53.77$537,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2015Anand MehraDirectorSell130,605$60.11$7,850,666.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2015Katherine A. HighinsiderSell30,000$49.34$1,480,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2015Katherine A. HighinsiderSell10,000$48.00$480,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2015Jeffrey D. MarrazzoCEOSell75,000$48.35$3,626,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2015Jeffrey D. MarrazzoCEOSell75,000$47.82$3,586,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2015Anand MehraDirectorSell529,544$45.46$24,073,070.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Coelho Rogerio VivaldiinsiderSell41,000$48.85$2,002,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Stephen W. WebsterCFOSell20,000$48.86$977,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Steven AltschulerDirectorBuy5,000$49.11$245,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015Anand MehraDirectorBuy225,000$23.00$5,175,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015Hospital Of Philade Children'sMajor ShareholderBuy100,000$23.00$2,300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015Stephen W WebsterCFOBuy2,500$23.00$57,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Spark Therapeutics (NASDAQ:ONCE)
DateHeadline
07/23/16 05:10 PMSpark Therapeutics : and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B
07/23/16 09:35 AMSpark Therapeutics : and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B.
07/22/16 05:31 PMInstitutional Investors Are Buying Islet Sciences Inc (NASDAQ:ONCE) - Consumer Eagle
07/22/16 05:31 PMEquity Roundup: Stock Performance Focus on Spark Therapeutics, Inc. (NASDAQ:ONCE) - Press Telegraph
07/22/16 05:31 PMSpark Therapeutics (ONCE), Pfizer (PFE) Receive FDA Breakthrough Therapy Designation for SPK-9001 as ... - StreetInsider.com
07/22/16 05:31 PMSpark Therapeutics Incorporated (NASDAQ:ONCE) Shorted Shares Decreased By 2.76% - Consumer Eagle
07/22/16 05:31 PMSpark Therapeutics, Inc. (NASDAQ:ONCE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 08:32 AMFDA Grants Breakthrough Therapy Designation For Spark, Pfizer's SPK-9001
07/21/16 06:48 AM13 Companies to Watch From MIT's Smart 50 List, Including 4 Buys -
07/21/16 06:30 AM7:30 am Spark Therapeutics and Pfizer (PFE) announce that the FDA has granted breakthrough therapy designation to SPK-9001 in development for the treatment of hemophilia B -
07/21/16 06:30 AMSpark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B - [GlobeNewswire] - PHILADELPHIA and NEW YORK, July 21, 2016-- Spark Therapeutics and Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted breakthrough therapy designation to SPK-9001, the lead ...
07/20/16 08:32 AMHeightened Volatility Spotted on Shares of: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Engelwood Daily
07/19/16 05:44 PMInsiders Selling, Short Interest Growing Spark Therapeutics, Inc. (NASDAQ:ONCE) - Finance Daily
07/19/16 07:01 AMSolid Performer in Focus: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Engelwood Daily
07/19/16 07:01 AMShare Performance Summary for: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Press Telegraph
07/19/16 07:01 AMRBC Capital Initiates Coverage on Spark Therapeutics Inc to Outperform - TheFounders Daily
07/19/16 07:01 AMIs $94 Price Target Attainable For Spark Therapeutics, Inc. (NASDAQ:ONCE)? - Investor Newswire
07/17/16 05:01 PMStock in Positive Territory for the Quarter: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Engelwood Daily
07/17/16 05:01 PMBroker Outlook For The Week Ahead Spark Therapeutics, Inc. (NASDAQ:ONCE) - Fiscal Standard
07/17/16 09:35 AM4 Speculative Biotech and Biohealth Analysts Calls for Huge Upside -
07/16/16 08:56 AMShares Experiencing a Downtrend: Spark Therapeutics, Inc. (NASDAQ:ONCE) - TGP
07/15/16 10:41 AMSpark Therapeutics, Inc. (NASDAQ:ONCE) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 10:41 AMAnalyst Target and Average Rating Watch: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Press Telegraph
07/15/16 10:41 AMSpark Therapeutics Inc Realized Volatility Hits Extreme Level - CML News
07/12/16 09:56 AMStock on the Rise for the Quarter: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Engelwood Daily
07/12/16 09:56 AMStock Performance Rundown on: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Press Telegraph
07/12/16 09:56 AMStrong Sell Calls For Spark Therapeutics, Inc. (NASDAQ:ONCE) At 1 - Investor Newswire
07/12/16 05:08 AMCoverage initiated on Spark Therapeutics by RBC Capital Mkts -
07/08/16 05:42 PMSpark Therapeutics, Inc. (NASDAQ:ONCE) Current Analyst Ratings - Fiscal Standard
07/08/16 05:42 PMSpark Therapeutics Announces Participation in Conferences in July - GlobeNewswire (press release)
07/08/16 08:35 AMSpark Therapeutics Incorporated (NASDAQ:ONCE) Sellers Increased By 4.76% Their Shorts - Engelwood Daily
07/08/16 08:35 AMCan Spark Therapeutics, Inc. (NASDAQ:ONCE) Improve on the Earnings Front? - Engelwood Daily
07/08/16 08:35 AMSpark Therapeutics, Inc. Upside Stock Momentum at Extreme Strength - CML News
07/08/16 08:35 AMCompany Stock Focus for Spark Therapeutics, Inc. (NASDAQ:ONCE): Which Way Will Shares Head? - Press Telegraph
07/08/16 08:35 AMPerformance Recap and Target Perspective on Spark Therapeutics, Inc. (NASDAQ:ONCE) - Press Telegraph
07/08/16 06:21 AMSpark Therapeutics Announces Participation in Conferences in July - [at noodls] - PHILADELPHIA, July 08, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) announced today that it will participate in the following conferences in July: Cantor Fitzgerald's 2nd Annual Healthcare ...
07/06/16 10:17 AMSpark Therapeutics, Inc. (NASDAQ:ONCE) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/06/16 10:17 AMStock Tracking Down This Month; Investor Alert on Spark Therapeutics, Inc. (NASDAQ:ONCE) - Engelwood Daily
07/05/16 12:09 PMETF’s with exposure to Spark Therapeutics, Inc. : July 5, 2016 -
07/05/16 10:06 AMShare Performance Recap for: Spark Therapeutics, Inc. (NASDAQ:ONCE) - Press Telegraph
07/02/16 05:16 PMSpark Therapeutics Incorporated (NASDAQ:ONCE) Sellers Increased By 4.76% Their Shorts - Press Telegraph
07/02/16 08:25 AMSpark Therapeutics Releases Positive Data On Most Advanced Product Candidate
07/01/16 05:40 PMSpark Therapeutics Inc Can't Burn Your Long Portfolio. Has Another Strong Session - Engelwood Daily
07/01/16 05:40 PMRecently Issued Stock Ratings For Spark Therapeutics, Inc. (NASDAQ:ONCE) - Fiscal Standard
07/01/16 08:25 AMSpark Therapeutics Announces Publication of Positive Follow-Up Data from Phase 1 Trial of Voretigene Neparvovec in The Lancet
06/30/16 05:55 PMNew Broker Ratings For Spark Therapeutics, Inc. (NASDAQ:ONCE) - FTSE News
06/30/16 05:55 PMEquity Research and Technical Review on Spark Therapeutics, Inc. (NASDAQ:ONCE) - Press Telegraph
06/30/16 05:55 PMSpark Therapeutics, Inc. (NASDAQ:ONCE) Earnings Glance and Target Price Review - Engelwood Daily
06/29/16 08:28 AMTop Stories: Spark Therapeutics, Inc. (NASDAQ:ONCE), Immune Design Corp. (NASDAQ:IMDZ), Dr Pepper Snapple ... - KC Register
06/28/16 05:35 PMWere Analysts Bearish Spark Therapeutics Inc (NASDAQ:ONCE) This Week? - Engelwood Daily

Social

About Spark Therapeutics

Spark Therapeutics logoSpark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). Its product candidates include SPK-CHM and SPK-FIX. Its product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. It is engaged in the development and commercialization of SPK-FIX product candidates for the treatment of hemophilia B. The Company is developing a lead product candidate for the treatment of a form of Batten disease in SPK-TPP1 program. The Company is also conducting preclinical studies on a product candidate for the treatment of Huntington's disease, a hereditary genetic disorder.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ONCE
  • CUSIP:
Key Metrics:
  • Previous Close: $54.68
  • 50 Day Moving Average: $51.33
  • 200 Day Moving Average: $39.01
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.50B
  • Beta: 3.3
  • Current Year EPS Consensus Estimate: $-3.81 EPS
  • Next Year EPS Consensus Estimate: $-3.59 EPS
Additional Links:
Spark Therapeutics (NASDAQ:ONCE) Chart for Sunday, July, 24, 2016